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Abstract 
Background: Treatment of the sub-clinical reservoir of malaria, which may maintain transmission, could be an 
important component of elimination strategies. The reliable detection of asymptomatic infections with low levels of 
parasitaemia requires high-volume quantitative polymerase chain reaction (uPCR), which is impractical to conduct on 
a large scale. It is unknown to what extent sub-clinical parasitaemias originate from recent or older clinical episodes. 
This study explored the association between clinical history of malaria and subsequent sub-clinical parasitaemia.
Methods: In June 2013 a cross-sectional survey was conducted in three villages in Pailin, western Cambodia. Demo-
graphic and epidemiological data and blood samples were collected. Blood was tested for malaria by high-volume 
qPCR. Positive samples were analysed by nested PCR to determine the Plasmodium species. To identify previous 
episodes of malaria, case records were collected from village malaria workers and local health facilities and linked to 
study participants.
Results: Among 1343 participants, 40/122 (32.8 %) with a history of clinical malaria were parasitaemic during the 
cross-sectional survey, compared to 172/1221 (14.1 %) without this history (p < 0.001). Among the 212 parasitaemic 
participants in the survey, 40 (18.9 %) had a history of clinical malaria, compared to 87 out of 1131 (7.7 %) parasite-
negative participants; p < 0.001, adjusted OR 3.3 (95 % CI; 2.1–5.1). A history of Plasmodium vivax was associated 
with sub-clinical P. vivax parasitaemia in the survey (p < 0.001), but this association was not seen with Plasmodium 
falciparum (p = 0.253); only three participants had both P. falciparum parasites in the survey and a clinical history of P. 
falciparum.
Conclusions: A clinical episode of vivax malaria was associated with subsequent sub-clinical parasitaemia. Treat-
ment of P. vivax with artemisinin-based combination therapy without primaquine often resulted in recurrent episodes. 
Targeting individuals with a history of clinical malaria will be insufficient to eliminate the sub-clinical reservoir as they 
constitute a minority of parasitaemias.
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Background
Pailin Province in western Cambodia was the first region 
where artemisinin-resistant Plasmodium falciparum was 
reported [1, 2]. Subsequently, artemisinin-resistant para-
sites have been found on the Thai-Myanmar border and 
recently in other parts of Southeast Asia [3]. In the past, 
P. falciparum strains resistant to chloroquine, sulfadox-
ine–pyrimethamine and mefloquine emerged in western 
Cambodia and spread across Southeast Asia to Africa 
[3–5]. Artemisinin-based therapy is globally the most 
effective of anti-malarials and first-line drugs for malaria. 
Artemisinin resistance poses a serious threat to malaria 
control [6]. There is an emerging consensus that prevent-
ing the spread of artemisinin-resistant malaria requires 
the elimination of all P. falciparum in areas of artemisinin 
resistance [7–9].
Malaria incidence in Pailin Province has dropped 
markedly over the last decade [10]. The incidence rate 
of malaria declined from 158/1000 cases per year in 
2004 to 13.1/1000 in 2011 (Provincial Health Depart-
ment, Pailin). Malaria control has improved over this 
period, including early treatment of clinical cases by vil-
lage malaria workers (VMWs), health education to raise 
awareness about malaria and the distribution of long-
lasting, insecticide-treated nets (LLINs) [10]. There have 
been multiple first-line malaria treatments in Cambodia 
over the past decade due to the rapid emergence and 
spread of resistant P. falciparum parasites [6, 11] (Appen-
dix: Table  7). Dihydroartemisinin-piperaquine is cur-
rently the first-line treatment for both uncomplicated P. 
falciparum and Plasmodium vivax in western Cambodia 
(Cambodian National Malaria Control Programme treat-
ment guidelines).
Recent studies demonstrate a large reservoir of sub-
microscopic malaria parasites in areas of low transmis-
sion in Southeast Asia [12, 13], including Pailin [14]. 
These sub-clinical levels of parasitaemia are likely to be 
an important source of transmission, and to be respon-
sible for the surge in clinical malaria at the start of the 
transmission season when vector capacity increases [12]. 
The estimate of malaria prevalence is dependent on the 
sensitivity of the detection method used. Parasite densi-
ties in asymptomatic carriers can often only be detected 
by polymerase chain reaction (PCR) techniques, which 
are expensive and time consuming [15]. A better under-
standing of the relationship between clinical malaria inci-
dence and asymptomatic malaria parasite prevalence is 
useful for planning cost-efficient surveillance strategies. 
If a large proportion of sub-clinical parasitaemias origi-
nate from previously treated malaria cases, then people 
with a history of malaria could be targeted as part of an 
elimination programme, and incident clinical cases of 
malaria could become a target for enhanced follow-up 
to achieve radical cure. Moreover, knowledge of the rela-
tionship between clinical and sub-clinical parasitaemia 
might allow an estimation of sub-clinical reservoirs. This 
study investigated to what extent sub-clinical parasitae-
mia was associated with past clinical episodes of malaria. 
The objective of this study was to describe and assess the 
association between symptomatic malaria and subse-
quent sub-clinical parasitaemia.
Methods
Sub‑clinical parasitaemia
A cross-sectional survey was conducted in June 2013 in 
three villages in Pailin Province in western Cambodia to 
estimate the prevalence of sub-clinical malaria parasitae-
mia. The neighbouring villages of Krachap Leu (KL), O 
Kting (OK) and Phnom Dambang (PDB) were selected 
because local treatment records indicated the highest 
malaria incidence within Pailin Province in 2012. Public 
meetings were held to inform the villages about the study 
and individual, written, informed consent was obtained 
from all participants or their guardians. Basic demo-
graphic, anthropometric and health history data were 
collected from everyone above 6 months of age who was 
in the villages during the 3 weeks of the study.
Laboratory procedures
Three ml venous blood samples from participants  ≥5 
years and 500  µl from children from 6  months up to 
5 years old were collected in EDTA tubes. Samples were 
stored in a cool box until transport to the Pailin Refer-
ral Hospital laboratory where they were centrifuged to 
separate plasma, buffy coat and packed red blood cells 
(pRBC). Each sample was labelled with a barcode to 
ensure blinding, then stored at −80  °C until transport 
on dry ice to the Mahidol University Faculty of Tropical 
Medicine molecular laboratory in Bangkok, Thailand.
Batches of 500 µl (~100 µl for those from 6 months up 
to 5 years) of pRBC were thawed and high-volume ultra-
sensitive qPCR (uPCR) was performed to detect malaria 
parasites. The uPCR technique (Qiagen, Germany) has a 
limit of accurate detection of 22 parasites/ml. [16] Para-
site density was quantified using the Rotor-Gene Q series 
software v 2.0.2. Samples testing positive for Plasmodium 
Keywords: Malaria, Plasmodium falciparum, Plasmodium vivax, Sub-clinical, Epidemiology, Quantitative polymerase 
chain reaction, Cambodia
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were then analysed by nested PCR to determine species 
[15, 16].
Symptomatic malaria
In each of the study villages VMWs used rapid diagnos-
tic tests (RDTs) and provided free treatment for malaria. 
They were supported by the mobile malaria work-
ers (MMWs) who provided the same services and were 
responsible for migrants. For each patient, demographic 
information (including whether resident or migrant) and 
the diagnosis and treatment given were recorded. The 
villages were in the catchment area of one peripheral 
health facility, Krachap Health Centre, which used RDTs 
to diagnose malaria. Severe cases of malaria were man-
aged by Pailin Referral Hospital, the only public hospital 
in Pailin. The hospital used microscopy for diagnoses. 
All available malaria case records relating to treatment 
of study participants prior to the June 2013 survey were 
collected from VMWs, MMWs, the Health Centre, and 
the Hospital. The records covered the period June 2005 
to 2013.
Case records were reviewed by two members of staff 
and then linked carefully to the survey participants 
by matching names, ages, gender, and where relevant, 
guardian. Correct linkage was confirmed by interview 
with the participant, their guardian, and/or the VMW 
or MMW who treated them. Linkage was finalized while 
blind to the participants’ parasitaemia status in the June 
2013 survey. Participants from the cross-sectional survey 
who responded that they were temporarily resident (and, 
therefore, would not reliably appear in local treatment 
records if treated for malaria prior to the survey) were 
excluded from the analysis.
Definitions
A case history of malaria was defined as having had clini-
cal malaria at some point prior to the cross-sectional sur-
vey as identified from the case records. A self-reported 
history of malaria was defined by the survey question 
“have you ever had malaria in the past?” and this cat-
egory could include people who did not otherwise appear 
in available malaria treatment records. Participants who 
tested positive for malaria parasites by qPCR in the cross-
sectional survey were defined as having sub-clinical para-
sitaemia. Each participant was asked whether they were 
temporarily (not a member of a permanent household) or 
permanently living in the village.
Statistical analysis
Groups were compared using a Student’s t test, the Chi 
squared test or Fisher’s exact test, as appropriate. The 
analysis was repeated using the proportion of all the sur-
vey participants who self-reported a history of malaria. 
The association between a case history of malaria and 
subsequent sub-clinical parasitaemia was quantified 
using logistic regression. All variables that were signifi-
cant in the univariate analysis at p < 0.05 were included 
in a logistic regression model with sub-clinical parasitae-
mia (Y/N) as the outcome. Using a stepwise approach, 
risk factors that were significant at p < 0.05 were identi-
fied and retained in the final model. Data were analysed 
using STATA, version 13.1 (StataCorp LP, College Sta-
tion, TX, USA).
Ethical approval
Ethics approval was obtained from the Oxford Tropi-
cal Research Ethics Committee (OXTREC; 1015-13), 
National Ethics Committee for Health Research Cambo-
dia (0029 NECHR), and the study was registered on clini-
caltrials.gov (NCT01872702).
Results
Cross‑sectional survey and case histories
In April 2013, the census population of the three vil-
lages was 1758. In June 2013, malaria test results and 
surveys were obtained from 1447 villagers (82.3  %). 
One-hundred and four migrants were excluded, leaving 
1343 participants for the main analysis (Fig. 1). A total 
of 410 malaria case records were collected: 258 from 
VMWs, 96 from the Health Centre, 45 from the Refer-
ral Hospital (of which 32 were from clinical studies), 
and 11 from MMWs, dating from 2005 to June 2013. Of 
410 case records, 122 (29.8 %) were linked to surveyed 
villagers. The quality of case records improved from 
2011 onwards after the strengthening of the VMW 
programme; 81/122 (66.4  %) of all the case records 
linked to survey participants come from 2011 onwards 
(Fig. 2).
Description of the study population
There were 212/1343 (15.8 %) participants with sub-clin-
ical parasitaemia at the time of the survey, and 122/1343 
(9.1  %) had a case history of malaria. Seventeen of 104 
(16.3 %) of the migrants surveyed had sub-clinical para-
sitaemia. Those who were aged >15 years, male or from 
Phnom Dambang village were more likely to have a his-
tory of malaria (Table 1) and also sub-clinical parasitae-
mia during the June 2013 survey [17, 18].
Recent travel to a forest and being a farmer with their 
own land were associated with a history of malaria 
(p < 0.001 and p = 0.002, respectively), but not with sub-
clinical parasitaemia (p =  0.614 and p =  0.068, respec-
tively). Mean age, travel history, use of bed nets, history 
of fever, history of illness and low-grade fever (tempera-
ture 37.5 °C or higher) were not associated with a history 
of malaria.
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Main outcome
The prevalence of any parasitaemia during the survey 
was higher (40/122 (32.8 %) among those with a recorded 
history of malaria when compared to those without 
[172/1221 (14.1 %), p < 0.001] (Table 2). The majority of 
people did not have sub-clinical parasitaemia in the sur-
vey and did not appear in local treatment records (Fig. 3). 
Among those with sub-clinical parasitaemia in the survey, 
Village populaon, June 2013 
n=1766
Blood sample not collected, 
n=23
Blood sample obtained, n=1447
malaria parasite
posive (n=40)
Recorded history of malaria (n=122)
Migrants, n=104
Did not parcipate in survey, 
n=296
malaria parasite 
negave (n=82)
No recorded malaria history (n=1221)
Analysed, n=1343
malaria parasite 
negave (n=1049)
malaria parasite
posive (n=172)
Fig. 1 Study consort diagram
Fig. 2 Time since treatment among those who were parasitaemic in the June 2013 survey and who also appeared in local health records as having 
been previously treated for malaria
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the odds ratio for a recorded history of malaria was 3.0 
(95 % CI; 2.0–4.5); after adjustment for age group, gender 
and village, the OR increased to 3.3 (95 % CI; 2.1–5.1).
In 140/212 sub-clinical parasitaemias, the species of 
malaria could not be determined by nested PCR. Where 
known, the most common species of sub-clinical parasi-
taemia was P. falciparum in those without a recorded his-
tory of malaria and P. vivax in those who did have a case 
history of malaria (Table 3). P. vivax and mixed P. vivax 
infections in malaria case records were strongly associ-
ated with P. vivax and mixed P. vivax parasitaemia dur-
ing the survey; p < 0.001 (Table 4). This association was 
not found between P. falciparum and mixed P. falciparum 
case records and P. falciparum and mixed P. falciparum 
parasitaemia during the survey, p = 0.253 (Table 5). Only 
three participants had a history of P. falciparum and 
were positive for P. falciparum in the survey. All of these 
cases occurred within the 6  months prior to the survey 
(Fig. 2). No association was found between the number of 
recorded malaria episodes and sub-clinical parasitaemia 
p = 0.300.
Self‑reported histories of clinical malaria
Of the participants who were linked to a malaria case 
record, 98.4  % (120/122) also self-reported having had 
malaria prior to the survey; 77.7  % (418/538) of those 
who self-reported having had malaria did not appear in 
the available malaria case records. Among these 418 par-
ticipants who reported malaria (but for whom no case 
record was found), there was a statistically significant 
association with sub-clinical parasitaemia during the 
survey [OR 1.5 (95  % CI; 1.1–2.0) p  =  0.023, Table  6]. 
This association was statistically non-significant when 
adjusted for age, gender and village (p = 0.100).
Discussion
In Pailin, sub-clinical parasitaemia with any malaria 
species was three times more common among those 
with a history of malaria than those without. This may 
be explained chiefly by the persistence or relapse of 
P. vivax parasites among previously treated cases, 
which suggests that treatment of P. vivax without pri-
maquine often fails to result in radical cure. There was 
no clear association between the case records of P. 
falciparum and subsequent sub-clinical P. falciparum 
parasitaemia in the survey. Only three participants had 
both a case record of P. falciparum and P. falciparum 
parasitaemia in the survey, and all had been infected 
within the previous 6 months.
The relationship between malaria incidence and the 
sub-clinical prevalence of parasitaemia is currently 
poorly defined. There were 55 malaria cases of all species 
Table 1 Baseline characteristics of  participants from  the 
June 2013 cross-sectional survey, by  recorded history 
of clinical malaria (2005–13)
* Comparing those with and without a clinical history of malaria
Case  
record of 
clinical 
malaria 
n = 122 
(9 %)
No case  
record of
 clinical 
malaria 
n = 1221 
(91 %)
All villagers
 n = 1343
P value*
Gender (male) 81 (66 %) 597 (49 %) 687 (51 %) <0.001
Age (years; mean) 26.8 24.1 24.3 0.107
Age groups (years)
 0–4.9 2 (2 %) 161 (13 %) 163 (12 %)
 5.0–14.9 31 (25 %) 334 (27 %) 365 (27 %)
 15.0–44.9 70 (57 %) 511 (42 %) 581 (43 %)
 ≥45.0 19 (16 %) 215 (18 %) 234 (17 %) <0.001
Village
 Krachap Leu 30 (25 %) 436 (36 %) 466 (35 %)
 O Kting 38 (31 %) 240 (20 %) 278 (21 %)
 Phnom Dam-
bang
54 (44 %) 545 (45 %) 599 (45 %) 0.004
Occupation
 Child or student 35 (29 %) 525 (43 %) 560 (42 %)
 Farmer other 
land
20 (16 %) 102 (8 %) 122 (9 %)
 Farmer own land56 (46 %) 443 (36 %) 499 (37 %)
 Farm labourer 8 (7 %) 101 (8 %) 109 (8 %)
 Other 3 (3 %) 50 (4 %) 53 (4 %) 0.002
Recent forest visit 11 (9 %) 38 (3 %) 49 (4 %) 0.001
Recent travel 
history
23 (19 %) 243 (20 %) 266 (20 %) 0.782
Bed net use
 Regular 118 (97 %) 1193 (98 %) 1311 (98 %)
 Irregular 4 (3 %) 28 (2 %) 32 (2 %) 0.496
Low grade 
fever ≥37.5 °C
4 (3 %) 69 (6 %) 73 (5 %) 0.270
Fever, by self-
report at survey
18 (15 %) 148 (12 %) 166 (12 %) 0.401
Illness, self-report 
at survey
32 (26 %) 371 (30 %) 403 (30 %) 0.334
Table 2 Association between  a case history of  malaria 
in  local health records (2005–13) and sub-clinical Plasmo-
dium parasitaemia in the June 2013 cross-sectional survey
p < 0.001
Case history 
of malaria
No case 
history of malaria
Total
Subclinical parasitae-
mia
40 (33 %) 172 (14 %) 212 (16 %)
No subclinical parasi-
taemia
82 (67 %) 1049 (86 %) 1131 (84 %)
Total 122 (100 %) 1221 (100 %) 1343 (100 %)
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recorded among residents of the study villages in 2012 
(an annual parasite incidence of approximately 4.1  %). 
The parasite prevalence during the uPCR survey in June 
2013 was 15.8  %, suggesting an approximately fourfold 
ratio. This information may be of relevance to elimination 
efforts as it could inform areas to target, but will require 
Table 3 Plasmodium species among sub-clinical parasitae-
mias in the June 2013 cross-sectional survey, by a case his-
tory of malaria in local health records (2005–13)
Plasmodium species Case history 
of malaria
No case history 
of malaria
Total
P. falciparum 0 0 0
Mixed P. vivax P. falcipa-
rum
5 (22 %) 18 (78 %) 23
P. vivax 1 (25 %) 3 (75 %) 4
Plasmodium, species not 
defined
18 (40 %)
16 (11 %)
27 (60 %)
124 (89 %)
45
140
Total 40 (19 %) 172 (81 %) 212 (100 %)
Table 4 Plasmodium vivax sub-clinical parasitaemia 
in  the June 2013 cross-sectional survey by  a case history 
of malaria in local health records (2005–13)
p < 0.001
P. vivax malaria 
case history
No P. vivax
 malaria case his‑
tory
Total
P.vivax subclinical 
parasitaemia
15 (18 %) 34 (3 %) 49 (4 %)
No P.vivax subclinical 
parasitaemia
70 (82 %) 1224 (97 %) 1294 (96 %)
Total 85 (100 %) 1258 (100 %) 1343
Table 5 Plasmodium falciparum sub-clinical parasitaemia 
in  the June 2013 cross-sectional survey by  a case history 
of malaria in local health records (2005–13)
p = 0.253
P. falciparum
 malaria case 
history
No P. falciparum 
malaria case his‑
tory
Total
P.falciparum subclini-
cal parasitaemia
3 (4 %) 24 (2 %) 27 (2 %)
No P.falciparum 
subclinical parasi-
taemia
77 (96 %) 1239 (98 %) 1316 (98 %)
Total 80 (100 %) 1263 (100 %) 1343
Table 6 Sub-clinical Plasmodium parasitaemia and  a self-
reported history of  clinical malaria recorded in  the cross-
sectional survey, among  those who did not have a case 
history of malaria in local health records
p = 0.023
Self‑reported
 history of malaria
No self‑reported 
history of malaria
Total
Subclinical parasi-
taemia
72 (17 %) 100 (12 %) 172 (14 %)
No subclinical para-
sitaemia
346 (83 %) 703 (88 %) 1049 (86 %)
Total 418 (100 %) 803 (100 %) 1221
Fig. 3 Recorded history of clinical malaria 2005–13 and subsequent parasitaemia in the June 2013 cross-sectional survey
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confirmation from other studies in other geographic 
areas. The origin of the large number of sub-clinical para-
sitaemias among those with no recorded or self-reported 
history of malaria remains unknown, as does the dura-
tion and potential infectiousness of sub-clinical P. falci-
parum parasitaemias in this population. The persistence 
of sub-clinical P. vivax parasitaemia among previously 
treated cases highlights again the critical importance of 
8-aminoquinolines for the complete cure. 8-aminoquino-
lines are currently not used widely in Cambodia due to 
concerns about haemolytic adverse effects among people 
with glucose-6-phosphate dehydrogenase deficiency.
Limitations
Prior to June 2011 VMW treatment records were not 
systematically collected. This missing information 
implies that this study may underestimate the association 
between treatment and sub-clinical parasitaemia. There 
is considerable seasonal migration in Pailin and case 
records of residents who received malaria treatment out-
side of the study area were not collected. Records could 
not be obtained from the private sector, where malaria 
treatment was common practice until it was banned in 
2012, and frequently involved the use of ineffective anti-
malarial drugs [19]. The sources from which case records 
were available generally followed the national guidelines 
for treatment of malaria, but the paucity of these data 
meant associations between specific anti-malarial drugs 
and subsequent sub-clinical parasitaemia could not be 
analysed. Data from the follow-up of clinical cases to 
assess efficacy at day 28 would have been informative, but 
were also unavailable. Lastly, parasite densities of sub-
clinical parasitaemia may be below the detection thresh-
old of uPCR and were missed in the cross-sectional 
design.
Conclusions
Clinical episodes of vivax malaria were associated with 
subsequent sub-clinical parasitaemia. Treatment of P. 
vivax with artemisinin-based combination therapy with-
out primaquine often resulted in recurrent episodes. The 
at least threefold risk of sub-clinical parasitaemia among 
those with a recorded case history of malaria suggests 
an easy-to-identify, high-risk population. Other high-
risk groups, such as family members of malaria cases or 
forest workers, have been identified by previous stud-
ies [14]. None of these groups constitute the majority of 
infections within the village population and many people 
harbour parasites but have no particular risk factors [17]. 
Therefore, to eliminate all malarias from an area, treat-
ment with the aim of interrupting transmission should 
target the entire community.
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Appendix
National Treatment Guidelines, Cambodia National 
Malaria Control Programme (see Table 7).
Table 7 Provincial Health Department guidelines for  first 
line antimalarial treatment in Pailin province
Drug policy period P. falciparum P. vivax
2002–2003 Artesunate-Mefloquine Chloroquine
2003–2010 DHA-PPQ Chloroquine
2010–2012 DHA-PPQ DHA-PPQ
2012–2014 Atovaquone-Proguanil DHA-PPQ
2014 DHA-PPQ DHA-PPQ
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